NASDAQ:GOSS Gossamer Bio (GOSS) Stock Forecast, Price & News $1.26 -0.04 (-3.08%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$1.23▼$1.3150-Day Range$0.98▼$1.5352-Week Range$0.91▼$15.20Volume1.42 million shsAverage Volume3.21 million shsMarket Capitalization$120.25 millionP/E RatioN/ADividend YieldN/APrice Target$7.32 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Gossamer Bio MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside480.8% Upside$7.32 Price TargetShort InterestBearish21.14% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingAcquiring Shares$802,713 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.87) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector313th out of 1,009 stocksPharmaceutical Preparations Industry143rd out of 494 stocks 3.2 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 5 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.32, Gossamer Bio has a forecasted upside of 480.8% from its current price of $1.26.Amount of Analyst CoverageGossamer Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.14% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 3.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 2.2 News and Social Media Coverage News SentimentGossamer Bio has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have bought 5,268.60% more of their company's stock than they have sold. Specifically, they have bought $802,713.00 in company stock and sold $14,952.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions90.18% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($1.87) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 9.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gossamer Bio (NASDAQ:GOSS) StockGossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.Read More Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Stock News HeadlinesMay 27, 2023 | americanbankingnews.comBrokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $6.35May 18, 2023 | finance.yahoo.comGossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International ConferenceMay 30, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 16, 2023 | americanbankingnews.comHC Wainwright Comments on Gossamer Bio, Inc.'s Q2 2023 Earnings (NASDAQ:GOSS)May 16, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) to Post Q2 2023 Earnings of ($0.48) Per Share, Wedbush ForecastsMay 13, 2023 | finance.yahoo.comIn the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actionsMay 11, 2023 | seekingalpha.comGossamer Bio GAAP EPS of -$0.52 beats by $0.02May 11, 2023 | msn.comHC Wainwright & Co. Reiterates Gossamer Bio (GOSS) Buy RecommendationMay 30, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 11, 2023 | seekingalpha.comGossamer Bio undergoes strategic restructuring; 25% of staff laid offMay 11, 2023 | markets.businessinsider.comGossamer Bio (GOSS) Receives a Buy from H.C. WainwrightMay 10, 2023 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Gossamer Bio (GOSS)May 9, 2023 | finance.yahoo.comGossamer Bio Announces First Quarter 2023 Financial Results and Provides Business UpdateApril 30, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) Receives $6.35 Average Target Price from AnalystsApril 6, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) CFO Bryan Giraudo Purchases 55,000 SharesApril 5, 2023 | americanbankingnews.comBrokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $7.14April 4, 2023 | finance.yahoo.comAfter Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma CandidateApril 3, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest UpdateMarch 25, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Buys 440,500 SharesMarch 25, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) to Post Q1 2023 Earnings of ($0.46) Per Share, HC Wainwright ForecastsMarch 24, 2023 | americanbankingnews.comBryan Giraudo Buys 50,000 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) StockMarch 24, 2023 | americanbankingnews.comWaage Christian Acquires 18,500 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) StockMarch 24, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Gossamer Bio, Inc. Increased by Analyst (NASDAQ:GOSS)March 24, 2023 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) CEO Buys $173,743.49 in StockMarch 23, 2023 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Gossamer Bio (NASDAQ:GOSS)March 22, 2023 | americanbankingnews.comHC Wainwright Weighs in on Gossamer Bio, Inc.'s FY2027 Earnings (NASDAQ:GOSS)March 22, 2023 | americanbankingnews.comCantor Fitzgerald Weighs in on Gossamer Bio, Inc.'s FY2023 Earnings (NASDAQ:GOSS)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Company Calendar Last Earnings11/08/2021Today5/30/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees185Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.32 High Stock Price Forecast$17.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+487.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-229,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,755.82% Return on Assets-83.17% Debt Debt-to-Equity Ratio17.20 Current Ratio5.19 Quick Ratio5.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book9.58Miscellaneous Outstanding Shares95,440,000Free Float87,522,000Market Cap$118.82 million OptionableNot Optionable Beta1.20 Key ExecutivesFaheem HasnainChairman, President & Chief Executive OfficerBryan GiraudoChief Operating & Financial OfficerChristian WaageEVP-Technical & AdministrationRichard ArandaChief Medical OfficerLaura CarterChief Scientific OfficerKey CompetitorsReviva PharmaceuticalsNASDAQ:RVPHAquestive TherapeuticsNASDAQ:AQSTESSA PharmaNASDAQ:EPIXEvofem BiosciencesNASDAQ:EVFMInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 797,936 shares on 5/18/2023Ownership: 0.125%Geode Capital Management LLCBought 51,145 shares on 5/16/2023Ownership: 1.411%Squarepoint Ops LLCSold 255,001 shares on 5/16/2023Ownership: 0.691%Sculptor Capital LPBought 114,000 shares on 5/16/2023Ownership: 0.000%Susquehanna International Group LLPSold 59,700 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GOSS Stock - Frequently Asked Questions Should I buy or sell Gossamer Bio stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares. View GOSS analyst ratings or view top-rated stocks. What is Gossamer Bio's stock price forecast for 2023? 10 brokers have issued twelve-month price objectives for Gossamer Bio's shares. Their GOSS share price forecasts range from $1.50 to $17.00. On average, they expect the company's stock price to reach $7.32 in the next twelve months. This suggests a possible upside of 480.8% from the stock's current price. View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts. How have GOSS shares performed in 2023? Gossamer Bio's stock was trading at $2.17 at the start of the year. Since then, GOSS stock has decreased by 41.9% and is now trading at $1.26. View the best growth stocks for 2023 here. When is Gossamer Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our GOSS earnings forecast. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.02. During the same period in the previous year, the company earned ($0.80) earnings per share. What ETF holds Gossamer Bio's stock ? WisdomTree BioRevolution Fund holds 2,078 shares of GOSS stock, representing 0.08% of its portfolio. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA). When did Gossamer Bio IPO? (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. What is Gossamer Bio's stock symbol? Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS." Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.02%), Palo Alto Investors LP (3.63%), Platinum Investment Management Ltd. (2.48%), Acadian Asset Management LLC (2.32%), Two Sigma Investments LP (1.96%) and Two Sigma Advisers LP (1.93%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gossamer Bio's stock price today? One share of GOSS stock can currently be purchased for approximately $1.26. How much money does Gossamer Bio make? Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $120.25 million. The company earns $-229,380,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. How many employees does Gossamer Bio have? The company employs 185 workers across the globe. How can I contact Gossamer Bio? Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com. This page (NASDAQ:GOSS) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.